Brensocatib Eligibility

This year we anticipate having the first-ever FDA-approved treatment for bronchiectasis—brensocatib.

Many have asked me about the criteria for brensocatib eligibility and it remains uncertain. The FDA will ultimately determine who can access it, whether by restricting it to high-risk populations or allowing clinicians more discretion in prescribing it.

For the clinical trial, participants had to be classified as frequent exacerbators—those experiencing two or more exacerbations per year requiring antibiotics. But that was just the trial’s criteria.

Going forward, clinicians will most probably ask for an open policy that will allow them to determine who might benefit most. After all, the mechanism of brensocatib in bronchiectasis is to reduce inflammation—and inflammation is at the core of this disease, regardless of exacerbation frequency.

In fact, many of us experience significant symptoms even without frequent exacerbations. So it stands to reason that reducing symptoms would improve quality of life and be a major benefit to our community.

Does this give you hope? Are you someone who likes to try new treatments right away, or do you prefer to wait, see how others respond, and then decide?

www.letsbecleartoday.com

#Bronchiectasis #brensocatib #clinicaltrials #AspenStudy #exacerbations #flareups #hopeisintheair